Researchers Identify Protein That May Limit CAR T-Cell Therapy Effectiveness
CAR T-cell therapy reprograms a patient's own immune cells to recognize and attack cancer cells. While the treatment has shown success against certain blood cancers, the engineered cells often become less effective as they develop an "exhausted" state.
Researchers have identified a protein called NFIL3 as